SXTC — China SXT Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $0.79m
- -$7.78m
- $1.97m
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7.01 | 5.16 | 4.78 | 2.6 | 1.97 |
Cost of Revenue | |||||
Gross Profit | 4.61 | 2.7 | 2.84 | 1.25 | 0.426 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 5.24 | 12.1 | 6.97 | 7.79 | 7.58 |
Operating Profit | 1.77 | -6.97 | -2.2 | -5.19 | -5.61 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1.79 | -10.4 | -2.94 | -5.41 | -5.93 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1.54 | -10.3 | -2.75 | -5.74 | -5.93 |
Net Income Before Extraordinary Items | |||||
Net Income | 1.54 | -10.3 | -2.75 | -5.74 | -5.93 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1.54 | -10.3 | -2.75 | -5.74 | -5.93 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 150 | -536 | -95.5 | -138 | -20.9 |